Li Watsek
Stock Analyst at Cantor Fitzgerald
(0.22)
# 4,359
Out of 4,534 analysts
115
Total ratings
39.4%
Success rate
-9.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMRX Immuneering | Initiated Coverage: Buy | $17 | $4.29 | +296.27% | 1 | Jul 8, 2026 | |
| ANL Adlai Nortye | Initiated Coverage: Buy | $28 | $11.98 | +133.72% | 1 | Jun 22, 2026 | |
| FTH Faeth Therapeutics | Maintained: Buy | n/a | $28.19 | - | 2 | Jun 3, 2026 | |
| ZLAB Zai Lab | Maintained: Buy | $37 | $20.52 | +80.31% | 8 | Apr 29, 2026 | |
| REPL Replimune Group | Downgraded: Hold | n/a | $10.51 | - | 5 | Apr 10, 2026 | |
| ASND Ascendis Pharma | Maintained: Buy | $300 | $251.76 | +19.16% | 24 | Apr 1, 2026 | |
| CRIS Curis | Rated: Hold | n/a | $4.52 | - | 4 | Mar 27, 2026 | |
| TYRA Tyra Biosciences | Maintained: Buy | n/a | $31.06 | - | 2 | Mar 4, 2026 | |
| AVBP ArriVent BioPharma | Initiated Coverage: Buy | n/a | $28.22 | - | 1 | Dec 22, 2025 | |
| CMPX Compass Therapeutics | Initiated Coverage: Buy | n/a | $2.02 | - | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $28.17 | - | 6 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $0.616 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.02 | - | 6 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $35.45 | - | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $10.68 | n/a | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $14.10 | n/a | 8 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.74 | n/a | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.00001 | n/a | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $4.07 | n/a | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.92 | n/a | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.16 | n/a | 5 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $0.2195 | n/a | 4 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $2.80 | n/a | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $5 | $0.0151 | n/a | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $71 → $38 | $2.57 | n/a | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 → $6 | $12.48 | n/a | 3 | Jun 28, 2022 |
Immuneering
Jul 8, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $4.29
Upside: +296.27%
Adlai Nortye
Jun 22, 2026
Initiated Coverage: Buy
Price Target: $28
Current: $11.98
Upside: +133.72%
Faeth Therapeutics
Jun 3, 2026
Maintained: Buy
Price Target: n/a
Current: $28.19
Upside: -
Zai Lab
Apr 29, 2026
Maintained: Buy
Price Target: $37
Current: $20.52
Upside: +80.31%
Replimune Group
Apr 10, 2026
Downgraded: Hold
Price Target: n/a
Current: $10.51
Upside: -
Ascendis Pharma
Apr 1, 2026
Maintained: Buy
Price Target: $300
Current: $251.76
Upside: +19.16%
Curis
Mar 27, 2026
Rated: Hold
Price Target: n/a
Current: $4.52
Upside: -
Tyra Biosciences
Mar 4, 2026
Maintained: Buy
Price Target: n/a
Current: $31.06
Upside: -
ArriVent BioPharma
Dec 22, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $28.22
Upside: -
Compass Therapeutics
Dec 3, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $2.02
Upside: -
Oct 8, 2025
Reiterated: Buy
Price Target: n/a
Current: $28.17
Upside: -
Oct 2, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $0.616
Upside: -
Sep 18, 2025
Reiterated: Buy
Price Target: n/a
Current: $8.02
Upside: -
Sep 9, 2025
Reiterated: Buy
Price Target: n/a
Current: $35.45
Upside: -
Jun 26, 2025
Reiterated: Buy
Price Target: n/a
Current: $10.68
Upside: n/a
Jun 12, 2025
Reiterated: Buy
Price Target: n/a
Current: $14.10
Upside: n/a
May 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $1.74
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.00001
Upside: n/a
Mar 14, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $4.07
Upside: n/a
Jan 24, 2025
Reiterated: Buy
Price Target: n/a
Current: $1.92
Upside: n/a
Jun 3, 2024
Reiterated: Buy
Price Target: n/a
Current: $4.16
Upside: n/a
Aug 30, 2023
Maintained: Buy
Price Target: $11
Current: $0.2195
Upside: n/a
Aug 9, 2023
Reiterated: Hold
Price Target: $5
Current: $2.80
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: $8 → $5
Current: $0.0151
Upside: n/a
Aug 12, 2022
Maintained: Buy
Price Target: $71 → $38
Current: $2.57
Upside: n/a
Jun 28, 2022
Maintained: Buy
Price Target: $16 → $6
Current: $12.48
Upside: n/a